Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $18.00 | Buy | BTIG Research |
Cohen and Associates is a highly respected neuropsychiatry clinic in western FloridaCohen to serve as foundational clinic in the Sarasota - Bradenton area of FloridaAcquisition expected to be immediately accretive to revenue and EBITDAMIAMI, June 26, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced the signing of a binding Letter of Intent (the "LOI") to purchase a 49% interest in Cohen and Associates, LLC ("Cohen"), founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE
AUSTIN, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- via IBN – NRx Pharmaceuticals Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. NRx Pharmaceuticals is advancing its patented NMDA receptor modulation platform through two investigational drugs: NRX-100 (preservative-free ketamine) and NRX-101 (D-cycloserine/lurasidone). These therapies have received FDA Fast Track and Breakthrough Therapy Designations, respectively, and target critical unmet needs in mental health—specifically suicidal depression and PTSD—for which no F
Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review requestCompany has received and complied with FDA information request for updated drug ingredient and label information on NRX-100Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preser
BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla
WILMINGTON, Del., May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the conference call will be av
Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world.
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
RW - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
S-3 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic
WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively. Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr
"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay GuptaDavid Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry fieldKadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closingDr. Feifel is expected to join HOPE as Chief Medical Innovation OfficerMIAMI, Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (NASDAQ:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was fea
SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)